bluebird bio Inc (NASDAQ: BLUE) is having a strong start to the trading session after it announced that it has entered into a collaboration with Regeneron Pharmaeuticals Inc (NASDAQ: REGN). Of course, the news excited investors, sending the stock on a run for the top. Today, we’ll talk about:
- The newly minted collaboration;
- what we’re seeing from BLUE stock as a result; and
- what we’ll be watching for ahead.
BLUE Announces Collaboration With REGN
As mentioned above, bluebird bio is having an incredibly strong start to the trading session this morning after the company announced a collaboration. In a press release issued early this morning, the company announced that it entered into a collaboration with Regeneron Pharmaceuticals to apply their respective technology platforms to the discovery, development and commercialization of immune cell therapies for cancer.
On the REGN side of the oin, the collaboration will leverage the company’s VelociSuite® platform technologies for the discovery and characterization of fully human antibodies, as well as T cell receptors (TCRs) directed against tumor-specific proteins and peptides. On the BLUE side of the coin, the company will contribute its field-leading expertise in gene transfer and cell therapy. In a statement, Philip Gregory, D.Phil, CSO at BLUE had the following to offer:
The collaboration with Regeneron complements bluebird bio’s growing immuno-oncology development portfolio, which includes clinical and pre-clinical CAR T and T cell receptor programs… With Regeneron’s proven targeting technologies, in combination with our deep expertise in cell biology and vector technology, as well as clinical experience with leading CAR T cell drug products, we hope to rapidly advance novel cellular therapies with the potential to transform the lives of people with cancer.
The above statement was followed up by George D. Yancopoulos, M.D., Ph.D., President and CSO at REGN. Here’s what he had to offer:
Like Regeneron, bluebird is a science-focused company looking to push the limits of what novel technologies can do in drug discovery and development… We believe that the tremendous synergies between Regeneron’s proven technologies and bluebird’s toolbox of advanced cell and gene therapy technologies create a promising opportunity to help people with cancer by developing innovative new treatments. This collaboration adds yet another dimension to our rapidly advancing portfolio of immuno-oncology candidates and combination approaches.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. In the case of BLUE, the news proved to be overwhelmingly positive. After all, this partnership could lead to strong revenue opportunities down the line. So, it only makes sense that we’re seeing gains in the value of the stock in the pre-market hours this morning. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:08), BLUE is trading at $158.00 per share after a gain of $8.01 per share or 5.34% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on BLUE and REGN. In particular, we’re interested in following the collaboration to see what new therapies come as a result. Nonehteless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!